Adocia Stock
Pros and Cons of Adocia in the next few years
Pros
Cons
Performance of Adocia vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Adocia | 5.570% | 0.119% | 0.357% | 198.761% | -28.231% | -7.151% | -54.378% |
| Valneva SE | 0.800% | -2.718% | -4.127% | -18.057% | -26.442% | -69.549% | 3.787% |
| Nanobiotix | -3.450% | 4.106% | -4.570% | 157.869% | -17.056% | -59.902% | -53.534% |
| Transgene S.A. | -4.120% | -10.526% | 15.625% | -29.799% | -6.119% | -49.376% | -56.471% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Diving into the financials of a company, such as Adocia from the Biotechnology & Medical Research industry, is akin to peering through a microscope for an in-depth examination of its fiscal health and market position. On a preliminary scan, the squad of numbers and ratios might seem daunting, but they hold the secrets to understanding the company's underlying story.
Starting off, one of the most striking observations in Adocia's financial statements is a consistently negative net income over the last three fiscal years. The trend is often an orange flag, signaling the potential for trouble on the horizon. The negative total stockholder equity further points towards a company that has, historically, been spending more than it's earning.
*The Pros: *
